Targeting the CD47-SIRPA Axis in Oncology, 2018: A Competitive Assessment of Technologies, Dual Targeting, Biomarkers, Combination Therapies & More –

The “Targeting
the CD47-SIRPA Axis in Oncology: A Competitive Assessment of
Technologies, Dual Targeting, Biomarkers, Combination Therapies & More”
report has been added to’s

Targeting the CD47-SIRP axis is emerging as one of the most promising
new cancer immunotherapy approaches seeking to target innate immune
response. This report reveals intense global interest and a growing list
of stakeholders operating in this field. Users of this report get an
un-biased, fact driven analysis of the position of each molecule and
commercial player, always kept up to date with twice weekly updates.

Most of the identified molecules in this report are either anti-CD47
antibodies or SIRP-Fc recombinant proteins. In healthy cells, CD47
serves as a “don’t eat me” signal by binding to the transmembrane SIRP
protein on phagocytic cells, preventing the engulfment of “self” by
macrophages. In several cancer types, tumor cells overexpress CD47 to
elude the immune system. Exploration of this property has been the
driving force to attract hundreds of million of dollars in investments
to companies like Tioma Therapeutics, Surface Oncology and Forty Seven,
the latter of which has just recently completed a $113 million IPO of
its common stock on June 26th, 2018. Deals in this area include the
early adopter move in 2012 by Celgene securing Inhibrx’ anti-CD47
antibody in a $500 million dollar deal to the recent billion dollar plus
agreement between OSE Immunotherapeutics and Boehringer Ingelheim.

On the clinical development front, this report identifies fewer than ten
molecules targeting the CD47-SIRP axis which have made it into the
clinic and so far with encouraging results. Several of these trials also
shed light on biomarker- and combination therapies of interest. On the
horizon, this field will soon have another injection of candidate
therapies with bispecific CD47 antibodies entering the clinic in late
2018 or early 2019.

Moreover, targeting the CD47-SIRP axis also has the potential to become
the combination therapy of choice as has already been demonstrated via
mediating longer survival in mice together with oncolytic virotherapy
and enhancing phagocytic capacity when used together with Carisma
Therapeutics’ CAR macrophages. Carisma Therapeutics themselves have just
announced a $53 million series A round of financing in order to develop
its novel CAR macrophage cellular immunotherapy and is estimating that
their project(s) will enter into the clinic in 2019.

Key Topics Covered

1 CD47-SIRPa Based Therapies in Oncology: An Overview

2 Startups Targeting the CD47-SIRPa Axis

3 Bispecific Drugs Targeting the CD47-SIRPa Axis

4 Deals & Alliances Among CD47-SIRPa Targeting Drugs

5 Phase II Pipeline Review & Analysis of CD47-SIRPa Based Therapies

6 Phase I Pipeline Review & Analysis of CD47-SIRPa Based Therapies

7 Preclinical Pipeline Review & Analysis of CD47-SIRPa Based Therapies

8 Discovery Pipeline Review & Analysis of CD47-SIRPa Based Therapies

9 CD47-SIRPa Based Therapies in Solid Tumors

10 CD47-SIRPa Based Therapies in non-Hodgkin’s Lymphoma

11 CD47-SIRPa Based Therapies in Acute Myelogenous Leukemia

12 CD47-SIRPa Based Therapies in Acute Lymphocytic Leukemia

13 CD47-SIRPa Based Therapies in Myeloma

For more information about this report visit

View source version on

Leave a Comment